Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up

Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up

Aim. Analysis of survival on biological therapy in previously bionaive patients with rheumatoid arthritis (RA) during the first year of therapy in real clinical practice. Materials and methods. The retrospective study included 204 adult patients with RA. In the hospital, patients were first prescr...

Full description

Bibliographic Details
Main Authors:	E. S. Aronova, G. V. Lukina, S. I. Glukhova, G. I. Gridneva, A. V. Kudryavtseva
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2020-06-01
Series:	Терапевтический архив
Subjects:	biological therapy drug survival gene-engineering biological drugs bdmards abatacept tocilizumab rituximab infliximab tumor necrosis factor-a blockers adverse events inefficacy rheumatoid arthritis
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/34584/pdf

Similar Items

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
by: Alisson Pugliesi, et al.
Published: (2023-07-01)

Biological Therapies in Inflammatory Myopathies
by: Abd El Haleem Natour, et al.
Published: (2023-04-01)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
by: Laetitia Diep, et al.
Published: (2022-10-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study
by: Alba Herrero-Morant, et al.
Published: (2020-08-01)

Are biological drugs safe in pregnancy?
by: A. Calligaro, et al.
Published: (2015-03-01)

Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
by: E. A. Strel’tsov
Published: (2018-10-01)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
by: Per Nived, et al.
Published: (2020-02-01)

The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease
by: Marina Yamashita, et al.
Published: (2023-11-01)

COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-01-01)

Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice
by: E. S. Aronova, et al.
Published: (2020-02-01)

Efficacy and tolerability of abatacept treatment: results of 12 months observation
by: M A Borisova, et al.
Published: (2018-05-01)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
by: Selma Tobudic, et al.
Published: (2023-02-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
by: Seogsong Jeong, et al.
Published: (2022-07-01)

Perspectives of the treatment of rheumatic diseases in the beginning of the XXI century
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-05-01)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
by: Denis Choquette, et al.
Published: (2019-06-01)

THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
by: D. G. Rumyantseva, et al.
Published: (2020-04-01)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
by: Matt Stevenson, et al.
Published: (2016-04-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Inefficacy of Language:A study in Beckett's Play –Waiting for Godot
by: .Ghanim Obeyed Oteiwey
Published: (2016-01-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01)

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
by: Ilaria Maccora, et al.
Published: (2022-04-01)

Ankilozan spondilit hastalarinda anemi sıklığının belirlenmesi ve biyolojik DMARD tedavisi ile değişimi
by: Asli Keles Onal, et al.
Published: (2021-09-01)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
by: Suzuki T, et al.
Published: (2018-03-01)

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
by: I. M. Marusenko, et al.
Published: (2019-03-01)

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
by: Szu-Hsuan Wang, et al.
Published: (2022-10-01)

Experience with abatacept used in the treatment of patients with rheumatoid arthritis
by: V I Mazurov, et al.
Published: (2011-12-01)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
by: Clement Triaille, et al.
Published: (2021-08-01)

Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review
by: Diego Fernández-Lázaro, et al.
Published: (2023-01-01)

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study
by: Jun Won Park, et al.
Published: (2022-02-01)

Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies
by: Yulia Rodina, et al.
Published: (2021-09-01)

CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting
by: Kuntheavy Ing Lorenzini, et al.
Published: (2021-08-01)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
by: Matthijs S. van der Leeuw, et al.
Published: (2022-03-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01)